Apellis (NASDAQ: APLS) insider plans 2203-share sale after 2618 sold
Rhea-AI Filing Summary
Apellis Pharmaceuticals insider plans to sell additional shares under Rule 144. A notice was filed to sell 2203 shares of common stock through Fidelity Brokerage Services LLC on or about 01/20/2026 on the NASDAQ market, with an aggregate market value of 43,603.76. The issuer had 126,525,218 common shares outstanding.
The 2203 shares to be sold were acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation. Over the prior three months, Nur Nicholson sold an additional 2618 common shares for gross proceeds of 58,086.09. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about Apellis Pharmaceuticals.
Positive
- None.
Negative
- None.